Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6770MR)

This product GTTS-WQ6770MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6770MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2875MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ8492MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ9974MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ10558MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ7302MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ11792MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ8280MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ9666MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW